HIV-positive TB patients on ART (antiretroviral therapy) in Indonesia
Indonesia: HIV-positive TB patients on ART (antiretroviral therapy) was 54.0% in 2024. ▲ Rising
HIV-positive TB patients on ART (antiretroviral therapy) in Indonesia, 2009–2024
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for hiv-positive tb patients on art (antiretroviral therapy) in Indonesia is 54.0%, measured in 2024. That is the highest value across all 16 years on record.
The figure is up 28.6% on the previous year and up 107.7% over ten years.
Over the whole period, hiv-positive tb patients on art (antiretroviral therapy) in Indonesia peaked at 54.0% in 2024 and was at its lowest, 21.0%, in 2015.
Indonesia ranks 138th of 144 countries on this measure, in the bottom quarter.
The long-run direction has been consistently rising across the 16 years of available data.
HIV-positive TB patients on ART (antiretroviral therapy) in Indonesia, year by year
| Year | Value | Change |
|---|---|---|
| 2009 | 42.0% | — |
| 2010 | 29.0% | -31.0% |
| 2011 | 39.0% | +34.5% |
| 2012 | 51.0% | +30.8% |
| 2013 | 47.0% | -7.8% |
| 2014 | 26.0% | -44.7% |
| 2015 | 21.0% | -19.2% |
| 2016 | 28.0% | +33.3% |
| 2017 | 29.0% | +3.6% |
| 2018 | 47.0% | +62.1% |
| 2019 | 47.0% | +0.0% |
| 2020 | 34.0% | -27.7% |
| 2021 | 40.0% | +17.6% |
| 2022 | 29.0% | -27.5% |
| 2023 | 42.0% | +44.8% |
| 2024 | 54.0% | +28.6% |
Indonesia compared with similar countries
- Indonesia's 54.0% is below the median for upper middle income countries, which is 93.0%, 58% of the median. (48 countries reporting)
- Indonesia's 54.0% is below the median for East Asia & Pacific, which is 92.0%, 59% of the median. (17 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 42.0% | 42.0% | 42.0% | 1 |
| 2010s | 36.4% | 21.0% | 51.0% | 10 |
| 2020s | 39.8% | 29.0% | 54.0% | 5 |
Countries ranked near Indonesia
More health data for Indonesia
- Un projection of annual infant deaths, annual growth rate -1.35 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.4924 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,286 deaths per 1,000 people (2090)
- Number of infants who die before age 1 16,463 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 50 (2025)
- Population ages 00-04, female, annual growth rate -0.5792 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0376 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.5519 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is hiv-positive tb patients on art (antiretroviral therapy) in Indonesia?
- Hiv-positive tb patients on art (antiretroviral therapy) in Indonesia was 54.0% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest hiv-positive tb patients on art (antiretroviral therapy) recorded in Indonesia?
- The highest recorded value was 54.0% in 2024.
- What is the lowest hiv-positive tb patients on art (antiretroviral therapy) recorded in Indonesia?
- The lowest recorded value was 21.0% in 2015.
- How does Indonesia rank for hiv-positive tb patients on art (antiretroviral therapy)?
- Indonesia ranks 138th out of 144 countries with data for 2024.
- Is hiv-positive tb patients on art (antiretroviral therapy) rising or falling in Indonesia?
- Over the last ten years it is up 107.7%. The long-run trend across the full record is rising.
- Where does this Indonesia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 16 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).